T he purpose of this review is to discuss the mechanisms by which vitamin D analogs alter cellular growth, with an emphasis on 1,25-dihydroxyvitamin D 3 [1, 25(OH) 2 D 3 ]-mediated regulation of growth factors and growth factor receptors. We believe this represents an important pathway by which vitamin D analogs change cellular growth in a variety of cells. It is well known that the primary function of 1,25(OH) 2 D 3 is the regulation of calcium and phosphorus metabolism (6) . The observation that 1,25(OH) 2 D 3 reduces the rate of cellular growth and induces the differentiation of myeloblasts (M1 cells) and promyelocytes (HL-60 cells) into macrophages (1) , and that 1,25(OH) 2 D 3 inhibits the proliferation of cancer cells (4) , initially showed that the sterol is capable of functioning in areas regulating cell functions distinct from transcellular calcium transport. The effects of 1,25(OH) 2 D 3 on the growth and differentiation of several different cell types have now been reported and suggest that 1,25(OH) 2 D 3 , or noncalcemic vitamin D analogs, may be of therapeutic value in the treatment of disorders characterized by abnormal cell growth.
The effects of vitamin D 3 and its metabolites on cells maintained in culture, or the effects observed after the topical application of vitamin D analogs to the skin at relatively high concentrations, stand in contrast to the effects of vitamin D deficiency seen in the whole organism. In vitamin D deficiency, growth retardation is a striking feature (7). These observations can be reconciled if one realizes that growth retardation in vitamin D deficiency is a consequence of calcium and phosphorus deficiencies. In vitamin D-dependent rickets type II, a disorder characterized by resistance to 1,25(OH) 2 D 3 because of mutations in the vitamin D receptor (VDR), calcium infusions increase the growth rate in affected children (2) . Recently, VDR null mutant mice were shown to be similar to their wild-type or heterozygous littermates in size, growth rate, and behavior at birth (10) because during gestation, sufficient transfer of calcium and phosphorus occurs across the placenta. Symptoms typical of rickets were seen in the null mutant mice after weaning, when non-vitamin D-dependent calcium transport mechanisms in the intestine are known to disappear (10) . Feeding null mutant mice a diet containing lactose and high concentrations of calcium overcomes the growth retardation seen in these animals. It should also be noted that the effects of 1,25(OH) 2 (8) .
1,25(OH) 2 D 3 regulates the expression of growth factors such as β-type transforming growth factors (TGF-β), insulin-like growth factor (IGF), nerve growth factor (NGF), glial cell line-derived neurotrophic factor, interleukins, hepatocyte growth factor and vascular endothelial growth factor (14) . Table 1 summarizes some of these effects; it is not comprehensive, and the reader is referred to other reviews for details (14) . These growth factors are expressed in many vitamin D-sensitive organs. Although information concerning the regulation of growth factors by 1,25(OH) 2 
1,25(OH) 2 D 3 , growth factors, and the skin
Several investigators have shown that 1,25(OH) 2 D 3 regulates the rate of proliferation of keratinocytes and skin fibroblasts in vitro and in vivo (8, 14) . 1,25(OH) 2 D 3 and noncalcemic vitamin D analogs are used in the treatment of hyperproliferative skin disorders such as psoriasis (8, 14) . The mechanism by which 1,25(OH) 2 D 3 decreases the growth of skin fibroblasts and keratinocytes, however, has not been clearly elucidated. We examined the effects of 1,25(OH) 2 D 3 on human keratinocyte proliferation and the role of growth factors in 1,25(OH) 2 D 3 -mediated control of keratinocyte growth (8) . When human keratinocytes are grown in a serum-free or defined culture medium, concentrations of 10 -8 M or greater of 1,25(OH) 2 D 3 , inhibit keratinocyte growth. Growth inhibition is not stringent but is exerted mainly in the G 1 phase of the cell cycle. The inhibition of cellular growth is associated with the differentiation and development of a more mature cellular phenotype. Interestingly, in defined medium where 1,25(OH) 2 D 3 is depleted and at lower or physiological concentrations (≤10 -9 M), cellular proliferation is enhanced. We have found that inhibition of cellular growth of human keratinocytes maintained in culture is caused by the release of TGF-β2 from cells (8) . A dose-dependent increase in TGF-β2 release and a dose-dependent decrease in cellular proliferation were observed when the cells were treated with 1,25(OH) 2 D 3 ; TGF-β1 and TGF-β3 concentrations did not increase. The addition of a pan-specific antibody against TGF-β partially blocked the growth inhibitory activities of the hormone, thus suggesting that at least some of the effects of 1,25(OH) 2 D 3 on growth were mediated via the release of TGF-β2.
1,25(OH) 2 D 3 , growth factors, and bone
TGF-β, along with systemic hormones and cytokines, regulates bone remodeling, bone fracture repair, bone induction, and development (12) . The amount of TGF-β in the bone of vitamin D-deficient rats is selectively reduced because of a deficiency of vitamin D and not calcium. Recently, we have shown that 1,25(OH) 2 D 3 causes a decrease in the growth of human osteoblasts, which is accompanied by an increase in the expression of TGF-β2 but not TGF-β1 (15) . Addition of an antibody directed against TGF-β partially blocks the growth inhibitory effects of 1,25(OH) 2 D 3 suggesting that the upregulation of TGF-β2 plays a role in the growth retardation seen after the treatment of osteoblasts with 1,25(OH) 2 D 3 . 1,25(OH) 2 D 3 -induced TGF-β2 expression is regulated at the level of gene transcription and increased TGF-β2 messenger RNA (mRNA) stability (15) . Interestingly, an increase in the amount of TGF-β type I and II receptor mRNA was also observed in osteoblasts treated with 1,25(OH) 2 D 3 (14) . Upregulation of TGF-β type I and II receptors could significantly contribute to 1,25(OH) 2 D 3 inhibition of osteoblast growth. In bone, the release of growth factors such as TGF-β likely influences the activity of cells adjacent to osteoblasts such as osteoclasts and thus may play an important role in bone remodeling (12) .
IGF-I and -II and insulin-like growth factor binding proteins (IGFBP) are regulated in bone by 1,25(OH) 2 D 3 (11, 12) . IGF-I and -II increase the synthesis of collagen in osteoblasts as well as increasing cell replication in bone (12 (11, 12) . In addition to effects on the release of IGF, 1,25(OH) 2 D 3 increases the number of type 1 IGF receptors in mouse clonal osteoblastic cells as well as upregulating the expression of IGFBP-2, -3, and -4 (11). The published findings do not allow a firm conclusion to be made as to how 1,25(OH) 2 D 3 influences bone cell growth via the IGF system.
1,25(OH) 2 D 3 , growth factors, and the prostate
As previously mentioned, 1,25(OH) 2 D 3 may be of therapeutic value in regulating disorders characterized by abnormal cell growth. In particular, 1,25(OH) 2 D 3 has been shown to regulate prostate cell proliferation, and recent studies have implicated vitamin D deficiency as a potential risk factor in the etiology of prostate cancer (5) . Although the precise mechanism is unclear, two recent studies suggest that TGF-β and IGFBP play a role in 1,25(OH) 2 D 3 -regulated prostate cell growth. 1,25(OH) 2 D 3 has been shown to increase TGF-β2 and TGF-β3 expression in NRP-152 cells, an epithelial cell line derived from rat prostate (5). Addition of a neutralizing TGF-β antibody was able to block the production of other 1,25(OH) 2 D 3 -regulated metabolites, suggesting that the upregulation of TGF-β plays a direct role in the effects of 1,25(OH) 2 D 3 on this cell line. In addition, 1,25(OH) 2 D 3 has been shown to increase the expression of IGFBP-6 in human prostate cells in a dose-dependent manner. It is possible that the mechanism for 1,25(OH) 2 D 3 -regulated prostate cell growth may ultimately involve both TGF-β and IGFBP.
1,25(OH) 2 D 3 , growth factors, and the nervous system
1,25(OH) 2 D 3 inhibits cell growth and induces NGF expression in cultured neuroblastoma cells, in glial cells, in rat brain in vivo, in cultured fibroblasts, and in osteoblasts (13) . NGF is secreted in a target-derived, paracrine manner, and subsequent binding of NGF to cell surface receptors on sensory, sympathetic, and central nervous system neurons results in a pleiotropic response that has been shown to be important for neuronal development and survival (3) 
Conclusions
Since the initial observation that 1,25(OH) 2 O ne of the most frequently occurring reactions in biology is the synthesis of ATP. The vast majority of this production is carried out by a nearly ubiquitous multisubunit complex. Whether in mitochondria, chloroplasts, or eubacteria, the F 0 F 1 ATP synthase couples the energy stored in the electrochemical gradient of protons (the proton motive force or ∆µ H + generated by electron transport chains) to form a highenergy phosphoanhydride bond from ADP and inorganic phosphate (P i ). The process of coupling the "downhill" transport of protons to the ATP synthesis reaction may be approached with the same thermodynamic considerations as the "classic" pumps, which are more commonly thought of as active transporters, such as the Ptype sodium/potassium or calcium ATPases. In fact, bacteria in anaerobic conditions utilize the F 0 F 1 in the reverse role as a primary proton pump using ATP derived from glycolysis to drive a ∆µ H +.
Structurally and mechanistically, however, the F 0 F 1 is quite different from the P-type pumps.
Understanding the molecular features of energy coupling in all active transport proteins remains an elusive goal. The long-standing nature of this problem has been caused in part by a dearth of structural information describing the large, integral membrane proteins, some of which are multiple-subunit complexes. Recently, the structural knowledge of the F 0 F 1 ATP synthase has dramatically increased. Although only a partial structure of the soluble F 1 domain was obtained from bovine mitochondria (1), the X-ray crystallographic structure at 2.8-Å resolution has led to several insights into the catalytic and coupling mechanisms. Furthermore, the structure has provided the basis for novel experimental approaches that have demonstrated the mechanical rotation of at least two subunits driven by the chemical reaction of ATP hydrolysis. From these experiments and others, it has become clear that rotary movement of a core of subunits is an integral part of the catalytic mechanism and probably 
